Therapeutic management of peritonitis;Prise en charge thérapeutique des péritonites

Medecine et Maladies Infectieuses

Volumn 34, Issue 5, 2004, Pages 183-195

  Bourgoin, A ^a   Leone, M ^a   Martin, C ^a  

^a HÔPITAL NORD   (France)

Author keywords

Anaerobic bacterium; Antibiotherapy; Antibioth rapie; Bact rie ana robies; Infection mixte; Mixed infection; Peritonitis; P ritonite

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIFUNGAL AGENT; AZTREONAM; CEFEPIME; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; ERTAPENEM; FLUCONAZOLE; GENTAMICIN; IMIPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULBACTAM;

ABSCESS; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BACTEROIDES FRAGILIS; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SCREENING; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EXPERIMENTAL MODEL; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PERITONEAL FLUID; PERITONITIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; REVIEW; SEPTIC SHOCK; SEPTICEMIA; SURVIVAL; TIME; TREATMENT INDICATION;

EID: 2542594654     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medmal.2004.03.002     Document Type: Short Survey

References (112)

1. Marshall J.C., Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med. 31:2003;2228-2237
2. Finegold S.M., Sutter V.L., Mathisen G.E. Normal indigenous intestinal flora. Hentges D.J. Human intestinal microflora in health and disease. 1983;3-31 Academic Press, New York
3. Leone M., Martin C. Antibiothérapie probabiliste des péritonites communautaires: influence du site. Ann Fr Anesth Réanim. 20:(Suppl. 2):2001;427-440
4. Nguyen J., Jarlier V. Épidémiologie bactérienne et intérêt des prélèvements microbiologiques périopératoires. Ann Fr Anesth Réanim. 20:(Suppl. 2):2001;395-399
5. Christou N.V., Turgeon P., Wassef R., Rotstein O., Bohnen J., Potvin M., et al. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg. 131:1996;1193-1201
6. Hopkins J.A., Lee J.C.H., Wilson S.E. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg. 59:1993;791-796
7. Mosdell D.M., Morris D.M., Voltura A., Pitcher D.E., Twiest M.W., Milne R.L., et al. Antibiotic treatment for surgical peritonitis. Ann Surg. 214:1991;543-549
8. Farthmann E.H., Schöffel U. Epidemiology and pathophysiology of intra-abdominal infections (IAI). Infection. 26:1998;329-334
9. Bosscha K., Van Vroonhoven T.J.M.V., Van Der Werken C. Surgical management of severe secondary peritonitis. Br J Surg. 86:1999;1371-1377
10. Nathens A.B., Rotstein O.D., Marshall J.C. Tertiary peritonitis: clinical features of a complex nosocomial infection. Word J Surg. 22:1998;158-163
11. Dupont H., Carbon C., Carlet J. for the severe generalized peritonitis study group. Monotherapy with a broad-spectrum betalactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother. 44:2000;2028-2033
12. Sotto A., Lefranc J.Y., Fabbro-Peray P., Muller L., Tafuri J., Navarro F., et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother. 50:2002;569-576
13. Levison M.E., Busch L.M. Peritonitis and other intra-abdominal infections. 4th Edition Mandell G.L., Bennett J.E., Dolin R. Infectious diseases. 1994;705-740 Churchill Livingstone, New York
14. Weinstein W.M., Onderdonk A.B., Barlett J.G., Gorlach S.L. Experimental intra-abdominal abscesses in rats. Development of an experimental model. Infect Immun. 10:1974;1250-1255
15. Holmdahl L., Ivarsson M.L. The role of cytokines, coagulation, and fibrinolysis in peritoneal tissue repair. Eur J Surg. 165:1999;1012-1019
16. Borgonovo G., Amato A., Varaldo E., Mattioli F.P. Définition et classification des péritonites. Méd Mal Infect. 25S:1996;7-12
17. Montravers P., Gauzit R., Muller C., Marmuse J.P., Fichelle A., Desmonts J.M. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 23:1996;486-494
18. Onderdonk A.B., Barlett J.G., Louie T., Sullivan-Seigler N., Gorlach S.L. Microbial synergy in experimental intra-abdominal abscess. Infect Immun. 13:1976;22-26
19. Dupont H., Montravers P., Mohler J., Carbon C. Enterococcus faecalis in mouse and rat models of peritonitis. Infect Immun. 66:1998;2570-2575
20. Nichols R.L., Muzik A.C. Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis. 15:1992;72-76
21. Burnett R.J., Haverstock D.C., Dellinger E.P., Reinhart H.H., Bohnen J.M., Rotstein O.D., et al. Definition of the role of Enterococcus in intra-abdominal infection: analysis of a prospective randomized trial. Surgery. 118:1995;716-721
22. Montravers P., Andremont A., Massias L., Carbon C. Investigation of the role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis. 169:1994;821-830
23. Rosenblatt J.E. Can we afford to do anaerobic cultures and identification? A positive point of view. Clin Infect Dis. 25:1997;S127-S131
24. Duerden B.J. Role of the reference laboratory in susceptibility testing of anaerobes and a survey of isolates referred from laboratories in England and Wales during 1993-1994. Clin Infect Dis. 20:1995;S180-S186
25. Onderdonk A.B., Bartlett J.G., Louie T., Sullivan-Seigler N., Gorbach S.L. Microbial synergy in experimental intra-abdominal abscess. Infect Immun. 13:1976;22-26
26. Onderdonk A.B., Weinstein W.M., Sullivan N.M., Bartlett J.G., Gorbach S.L. Experimental intra-abdominal abscesses in rats. Quantitative bacteriology of infected animals. Infect Immun. 10:1974;1256-1259
27. Matlow A.G., Bohnen J.M.A., Nohr C., Christou N., Meakins J. Pathogenicity of entroccoci in a rat model of fecal peritonis. J Infect Dis. 160:1989;142-145
28. Rostein O.D., Kaoj Housjonk. Reciprocal synergy between Escherichia coli and Bacteroides in an intra-abdominal infection model. J Med Microbiol. 29:1989;269-276
29. Weinstein W.M., Onderdonk A.B., Bartlett J.G., Loie T.J., Borbach S.L. Antimicrobial therapy of experimental intra-abdominal sepsis. J Infect Dis. 162:1975;282-286
30. Dalhoff A. Therapy of infections caused by mixed of Escherichia coli and Steptococcus faecalis. Curr Microbiol. 7:1982;275-280
31. Willey S., Hindes R., Eliopoulous G., Moellering R.C. Jr. Effects of clindamycin and gentamicin and other anti-microbial combinations against enteroccci in an experimental model of intra-abdominal abscess. Surg Gynecol Obstet. 169:1989;199-202
32. Xells C., Jechorek R., Maddaus M., Simmons R. Effects of clindamycin and metronidazole on intestinal colonization and translocation of enteroccoci in mice. Antimicrob Agents Chemother. 169:1989;199-205
33. Barie P.S., Christou N.V., Dellinger E.P., Rout W.R., Stone H.H. Pathogenicity of the Enterococcus in surgical infections. Ann Surg. 212:1990;155-159
34. Tailor S.A.N., Bailey E.M., Rybak M.J. Enterococcus, an emerging pathogen. Ann Pharmacoth. 27:1993;1231-1242
35. Barrull D.T., Kenney P.R., Stotman G.J., Buchard K.W. Enterococcal bacteremia in surgical patients. Arch Surg. 120:1985;57-63
36. Wells C.L., Jechorek R.P., Erlandsen S.L. Evidence for the translocation of Enterococcus faecalis across the mouse intestical tract. J Infect Dis. 162:1990;82-90
37. Dupont H, Montravers P, Mohler J, Carbon C. Disparate findings on the role of virulence factors of Enterococcus faecalis in mouse and rate models of peritonitis.
38. Marchou B., Michea-Hamzehpour M. Development of β-lactam resistant Enterobacter cloacae in mice. J Infect Dis. 156:1978;369-373
39. Pechere J.C. Emergence of resistance during β-lactam therapy of Gram-negative infections. Bacterial mechanisms and medical responses. Drugs. 35:(Suppl. 2):1992;22-28
40. Anonyme. Prise en charge des péritonites communautaires. Ann Fr Anesth Reanim. 20:(Suppl. 2):2001;337-472
41. Gerding D.N., Olson M.V., Johnson S., Peterson L.R., Lee J.T. Jr. Clostridium difficile diarrhea and colonization after treatment with abdominal regimens containing clindamycin or metronidazole. Am J Surg. 159:1991;212-217
42. Canadian metronidazole-clindamycine study group. Prospective, randomizde comparaison of metronidaozle et clindamycine, each with gentamycine, for the treatment of serious intra-abdominal infection. Surgery. 93:1983;221-229
43. King D.R., Browne A.F., Birken G.A., Hilty M.D., Kerzner B., Boles E.T. Antibiotic management of complicated appendicitis. J Pediatr Surg. 18:1983;945-950
44. Study group of intra-abdominal infections. A randomised controlled study trial of ampicillin plus sulbactam vs. Gentamycin plus clindamycin in the treatment of intra-abdominal infections: a preliminary study report. Rev Infect Dis. 8:1986;S583-S588
45. Yellin A.E., Heseltine P.N., et al. The role of pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet. 161:1985;303-307
46. Pourriat J.L. Infection intra-abdominales, place de l'Augmentin® Lettre de l'infectiologue. (HS février):1995;27-28
47. Sirinek K.R., Levine B.A. A randomized trial of ticarcillin and clavulanate vs gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet. 172:(Suppl):1991;30-35
48. Fink M.P. Antibiotic therapy of intra-abdominal sepsis in the elderly: experience with ticarcillin and clavulanic acid. Surg Gynecol Obstet. 172:(Suppl):1991;36-41
49. Dougherty S.H., Sirinek, Shauer P.R., Fink M.P., Fabian T.C., Martin D.H., et al. Tircacillin/clavulanate compared with clindamycin-aminoglyciside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet. 154:1982;715-720
50. Ohlin B., Cedeberg A., Forseell H., Solhaug J.H., Tveit E. Piperacillin-tazobactam compared with cefuroxime-metronidazole in the treatment of intra-abdominal infections. Eur J Surg. 165:1999;875-884
51. Polk H.C. Jr, Fink M.P., Laverdiere M., Wilson S.E., Garber G.E., Barie P.S., et al. The Piperacillin-Tazobactam intra-abdominal Infection Study Group. Prospective randomized study of piperacillin-tazobactam therapy of surgically treated intra-abdominal infection. Am Surg. 59:1993;598-605
52. Brismar B., Malmborg A.S., Tunevall G., Wretlind B., Bergman L., Mentzing L.O., et al. Piperacillin-tazobactam vs imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother. 36:1992;2766-2773
53. Niinikoski J., Havia T., Alhava E., Paakkonen M., Miettinen P., Kivilaakso E., et al. Piperacillin-tazobactam versus imipenem-cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet. 176:1993;255-261
54. Busuttil R.W., McGrattan M.A., Freischlag J. A comparative study of cefamandole vs gentamycin plus clindamycin in the treatment of documented or suspected bacterial peritonitis. Surg Gynecol Obstet. 158:1984;1-8
55. Schropp K.P., Kaplan S., Golladay E.S., King D.R., Pokorny W., Mollitt D.L., et al. A randomized clinical trial of ampicillin, gentamicin and clindamycin vs cefotaxime and clindamycin in children with ruptured appendicitis. Surg Gynecol Obstet. 172:1991;351-356
56. Huizinga W.K., Warren B.L., Baker L.W., Valleur P., Pezet D.M., Hoogkamp-Korstanjep J.A., et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother. 36:(Suppl. A):1995;179-189
57. Hoogkam-Korstanjep J.A. Ciprofloxacin vs Cefotaxime regimens for the treatment of intra-abdominal infections. Infecetion. 23:1995;278-282
58. Stone H.H., Morris E.S., Geheber C.E., Kolb L.D., Dunlop W.E. Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections. Rev Infect Dis. 4:1982;S439-S443
59. Barie P.S., Vogel, Dellinger E.P., Rostein O.D., Solomkin J.S., Yang J.Y., et al. Cefepime intra-abdominal Infection Study Group. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastin in the treatment of complicated intra-abdominal infections. Arch Surg. 132:1997;1294-1302
60. Berne T.V., Yellin A.E., Appleman M.D., Heseltine P.N., Gill M.A. A clinical comparison of cefepime and metronidazole vs gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet. 177:(Suppl):1993;18-22
61. Christou N.V., Turgeon P., Wassef R., Rostein O., Bohnen J., Potvin M., et al. Management of intra-abdominal infections. Arch Surg. 131:1996;1193-1201
62. Walker A.P., Nichols R.L., Wilson R.F., Bivens B.A., Trunkey D.D., Edmiston C.E., et al. Efficacy of betalactamase inhibitor combination for serious intra-abdominal infections. Ann Surg. 217:1993;115-121
63. Drusano G.L., Warren J.W., Saah A.J., Caplan E.S., Teney J.H., Hansen S., et al. A prospective randomized controlled trial of cefoxitin vs clindamycin-aminoglycoside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet. 154:1982;715-720
64. Malangoni M.A., Condon R.E., Spiegel C.A. Treatment of intra-abdominal infections is appropriate with single-agent or combination antibiotic therapy. Surgery. 98:1985;648-655
65. Lewis R.T., Duma R.J., Echols R.M., Jemsek J.G., Najem A.Z., Press R.A., et al. Comparative study of cefotetan and cefoxitin in the treatment of intra-abdominal infections. Am J Obstet Gynecol. 158:1988;728-735
66. Huizinga W.K.J., Baker L.W., Kadwa H., Van Den Ende J., Francis A.J., Francis G.M. Management of severe intra-abdominal sepsis: single agent antibiotic therapy with cefotetan vs combination therapy with ampicilline, gentamycin and metronidazole. Br J Surg. 75:1988;1134-1138
67. Condon R.E., Walker A.P., Sirinek K.R., White P.W., Fabian T.C., Nichols R.L., et al. Meropenem vs tobramycin plus clindamycin for treatment of intra-abdominal infections: results of prospective, randomized, double-blind clinical trial. Clin Infect Dis. 21:1995;544-550
68. Wilson S.E. Results of a randomized, multicenter trial of meropenem versus clindamycin-tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis. 24:(suppl. 2):1997;S197-206
69. Solomkin J.S., Dellinger E.P., Christou N.V., Busuttil R.W. Results of a multicenter trial comparing imipenem-cilastatin against tobramycin-clindamycin for intra-abdominal infections. Ann Surg. 212:1990;581-591
70. Solomkin J.S., Reinhart H.H., Dellinger E.P., Bohnen J.M., Rotstein O.D., Vogel S.B., et al. The intra-abdominal infection Study group. Results of a randomized trial comparing sequential intraveinous/oral treatment with ciprofloxacin plus metronidazole to imipenem-cilastatin for intra-abdominal infections. Ann Surg. 223:1996;303-315
71. Kempf P., Bauernfeind A., Muller A., Blum J. Meropenem monotherapy vs cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. Infection. 24:1996;473-479
72. Sitges-Serra A., Guirao X., Diaz J., Azanza R., Noriega A.R., Lizasain M., et al. Comparcion prospective, aleetoria y aberta de meropenem frente a cefotaxima y metronidazol en el tratamiento de las infecciones intra-abdominales. Med Clin. 111:1998;88-91
73. Chang D.C., Wilson S.E. Meta-analyse of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg. 174:1997;284-290
74. Eckhauser F.E., Knol J.A., Raper S.E., Mulholland M.W., Helzerman P. Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: results of a multicenter study. Clin Ther. 14:1992;97-109
75. Gonzenbach H.R., Simmen H.P., Amgwerd R. Imipenem (N-F-Tienamicin) vs netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections. Ann Surg. 205:1987;271-275
76. Poenaru D., De Santis M., Christou N.V. Impenem vs tobramycin- antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg. 33:1990;415-422
77. Solomkin J.S., Yellin A.E., Rotsein O.D., Christou N.V., Dellinger E.P., Tellado J.M., et al. Ertapenem versus piperacilline-tazobactam in the treatment of complicated intra-abdominal infections. Results of a double-blind, randomized comparative phase III trial. Ann Surg. 237:2002;235-245
78. Berne T.V., Yellin A.E., Appleman M.D., Gill M.A., Chenella F.C., Heseltine P.N. Surgically treated gangrenous or perforated appendicitis: A comparison of aztreonam and clindamycin vs gentamycin and clindamycin. Ann Surg. 205:1987;133-137
79. Birolini D., Moraes M.F., De Souza O.S. Aztreonam plus clindamycin vs tobramycin plus clindamycin for the treatment of intra-abdominal infections. Rev Infect Dis. 7:(Suppl. 4):1985;S724-S728
80. Cohn S.M., Lipsett P.A., Buchman T.G., Cheadle W.G., Milsom J.W., Kowalsky S.F., et al. Comparison of intravenous-oral ciprofloxacin plus metronidazole vs piperacillin-tazobactam in the treatment of complicated intra-abdominal infection. Ann Surg. 232:2000;254-262
81. Yoshioka K., Youngs D.J., Keighley M.R. A randomised prospective controlled study of ciprofloxacine with metronidazole vs amoxicilline-clavulanic Acid with metronidazole in the treatment of intra-abdominal infection. Infection. 19:1991;25-29
82. Starakis I., Karravias D., Asimakopoulos C., Kolaras P., Nikolaidis P., Harlaftis N., et al. Results of a prospective, randomised, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous-oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous) + metronidazole (intravenous-oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents. 21:2003;49-57
83. Bohnen J.M., Mustard R.A., Oxholm S.E., Schouten B.D. APACHE II score and abdominal sepsis. A prospective study. Arch Surg. 123:1988;225-229
84. Dalmau D., Layrargues G.P., Fenyves D., Willems B., Turgeon F., Turgeon P. Cefotaxime, desacetyl-cefotaxime, and bactericidal activity in spontaneous bacterial peritonitis. J Infect Dis. 180:1999;1597-1602
85. Nguyen Van J.C., Collet L., Chardon H., Jarlier V. Étude de la sensibilité à l'Augmentin de 998 souches de Escherichia coli isolées dans quatre centres hospitaliers français (Étude Colicerib I). Méd Mal Infect. 24:1994;765-773
86. Vedel G., Belaaouaj A., Gilly L. Clinical isolates of Escherichia coli producing TRI betalactamases: novel TEM-enzymes conferring resistance to betalactamase inhibitors. J Antimicrob Chemother. 30:1992;449-462
87. Dubreuil L. Bacteroides fragilis: état de la sensibilité aux antibiotiques, évolution des résistances. Méd Mal Infect. 26:1996;196-207
88. Klepser M.E., Marangos M.N., Zhu Z., Nicolau D.P., Quintiliani R., Nightingale C.H. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 41:1997;435-439
89. Maltezou H.C., Nikolaidis P., Lebesii E., Dimitriou L., Androulakakis E., Kafetzis D.A. Piperacillin/Tazobactam vs cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 20:2001;643-646
90. Montravers P. Antibiothérapie des péritonites communautaires. Ann Fr Anesth Réanim. 20:(Suppl. 2):2001;411-426
91. Bath X., Hayoun H., Rat P., Hoen J.P., Favre J.P., Lombard-Platet R. Comparaison de deux associations d'antibiotiques au cours des péritonites: céfotaxime + clindamycine vs céfotaxime + métronidazole. Presse Med. 20:1991;57-60
92. Biron S., Brochu G., Beland L., Bourque R.A., Marceau P., Piche P., et al. Short-term antibiotherapy for peritonitis: prospective, randomized trial comparing cefotaxime-metronidazole and clindamycin-tobramycin. J Antimicrob Chemother. 14:(Suppl. B):1984;213-216
93. Luke M., Iversen J., Sandergaard J., Kvist E., Lund P., Andersen F., et al. Ceftriaxone-metronidazole is more effective than ampicillin-netilmicin- metronidazole in the treatment of bacterial peritonitis. Eur J Surg. 157:1991;397-401
94. Aprahamian C., Schein M., Wittmann D. Cefotaxime and metronidazole in severe intra-abdominal infection. Diagn Microbiol Infect Dis. 22:1995;183-188
95. Broze B., De Mees J., Droissart R., Nolens V.P., Staudt J.P., Verstraten M.E., et al. Traitement empirique des infections intra-abdominales sévères: étude multicentrique comparative de l'efficacité de l'imipénème-cilastatine et de la ceftazidime. Acta Clin Belg. 42:1987;431-436
96. Bubrick M.P., Heim-Duthoy K.L., Yellin A.E., Berne T.V., Heseltine P.N., Appleman M.D., et al. Ceftazidime-clindamycin vs tobramycin-clindamycin in the treatment of intra-abdominal infections. Am Surg. 56:1990;613-617
97. Bochud P.Y., Glauser M.P., Calandra T. Antibiotics in sepsis. Intensive Care Med. 27:(Suppl. 1):2001;S33-S48
98. Montravers P., Veber B., Dupont H., Blin P., Gauzit R., Guillou Y.M., et al. Aspects épidémiologiques et thérapeutiques des péritonites fongiques communautaires (PFC) et postopératoires (PFPO). Ann Fr Anesth Réanim. 20:(Suppl. 1):2001;248s. (R415)
99. Solomkin J.S., Flohr A.B., Quie P.G., Simmons R.L. The role of Candida in intraperitoneal infections. Surgery. 88:1980;524-530
100. Geroulanos S.J. Meropenem Study Group. Meropenem vs imipenem-cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother. 36:(Suppl. A):1995;191-205
101. Cometta A., Baumgartner J.D., Lew D., Zimmerli W., Pittet D., Chopart P., et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother. 38:1994;1309-1313
102. Eklund A.E., Nord C.E. Swedish Study Group. A randomized multicenter trial of piperacillin-tazobactam vs imipenem-cilastatin in the treatment of severe intra-abdominal infections. J Antimicrob Chemother. 31:(Suppl. A):1993;79-85
103. Pefanis A., Thauvin-Eliopoulios C., Holden J., Eliopoulios G.M., Ferrard M.J., Moellering R.C. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses. Antimicrob Agents Chemother. 34:1994;252-258
104. Dupont H., Paugam-Burtz C., Muller-Serieys C., Chosidow D., Mantz J., Desmonts J.M. Facteurs prédictifs de mortalité des péritonites graves en réanimation. Ann Fr Anesth Réanim. 19:(Suppl. 1):2000;287s. (R497)
105. Bourichon A., Dupont H., Paugam-Burtz C., Beloucif S., Mantz J., Desmonts J.M. La présence de levures dans les péritonites peut être prédite par un score. Ann Fr Anesth Réanim. 20:(Suppl. 1):2001;248s. (R416)
106. Wittmann D.H., Schein M., Codon R.E. Management of secondary peritonitis. Ann Surg. 224:1996;10-18
107. Bohnen J., Solomkin J., Dellinger E., Bjornson S., Page C. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. Arch Surg. 127:1992;83-89
108. Melcher G.A., Ruedi T.P. Duration of antibiotic treatment in surgical infections of the abdomen. Blunt abdominal trauma. Eur J Surg. 576:(Suppl):1996;59-60
109. Fabian T.C., Croce M.A., Payne L.W., Minar G., Pritcard F.E., Kudsk K.A. Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery. 112:1992;788-794
110. Kirton O.C., O'Neill P.A., Kestner M., Tortella B.J. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, double-blind, placebo-control trial of 24 hours vs five days. J Trauma. 49:2000;822-832
111. Schein M., Assalia A., Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg. 81:1994;989-991
112. Barlett J.G. Intra-abdominal sepsis. Med Clin North Am. 79:1995;599-617